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Introduction

The problem of opiate addiction is complex enough but compounded when the
patient is pregnant. Substance use during pregnancy produces harmful and costly effects
to both the mother and the fetus (Veilleux, Colvin, Anderson, York & Hines, 2010).
The rate of opiate addiction among pregnant women in the U.S. has been increasing in
epidemic numbers since the beginning of the 21st century. This paper looks at research
on the origin of the problem, the demographics of the average pregnant opiate addicted
patient, the effects on the woman and her unborn child, and available treatment options.
Preparation at the practice doctorate level includes advanced education to help
become a change agent for populations in need, such as pregnant opiate addicted women
and their unborn children. The DNP prepared nurse is well positioned to assist this
vulnerable population by using expert knowledge to influence health care outcomes for
the pregnant opiate addicted patients. This specific population is often ostracized and
stigmatized which can deter their seeking available treatment. As an example, in 2014, a
law was passed in Tennessee that allows women to be criminally charged with an
assaultive offense for the illegal use of a narcotic drug while pregnant or if her child is
born addicted to or harmed by the narcotic drug; and for criminal homicide if her child
dies as a result of her illegal use of a narcotic drug taken while pregnant. A felony
assault charge can subject such woman up to 15 years in prison in Tennessee.
Further, pregnant opiate addicted women face stigma from healthcare
professionals. As an example, a systematic review of 28 studies examining stigma by
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healthcare professionals toward patients with substance use disorders concluded that
negative attitudes of healthcare professionals toward patients with substance use
disorders are common and contribute toward suboptimal outcomes (Van Boekel,
Brouwers, Van Weeghel, and Garretson, 2013). The DNP prepared nurse has a unique
opportunity to contribute to positive treatment outcomes by providing direct care and
assist with the management of care for these individuals. In addition, the DNP prepared
nurse can develop and implement healthcare policies to enhance access to often sparsely
available and expensive care.
Application of the DNP Essentials led to the development of this project. In
examining DNP Essential Number V, Health Care Policy for Advocacy in Health Care, it
became apparent that this Essential would be instrumental in making effective changes
for the population at hand. Therefore a thorough investigation of the policy underlying
drug addiction treatment methods and availability was conducted.
DNP Essential III, Clinical Scholarship and Analytical Methods for EvidenceBased Practice was also used to develop this project and find solutions for the treatment
needs of the population. The population of pregnant opiate addicted women is an area
where a gap in literature exists, in terms of their experience and their needs for treatment.
Information on the effects of the use of drugs on the fetus is readily available but not on
preferred treatment methods and treatments that actually work for this group of women.
This practice inquiry project will further present three manuscripts that explore
the issue of opiate drug addiction. The first manuscript is an integrative review of the
literature regarding pregnancy and opiate addiction. It examines research that focuses on
the issues faced by pregnant women who use and abuse opiates, such as access to care,

vii

drug replacement therapy, and neonatal abstinence syndrome.
The second manuscript analyzes the role of the advanced practice nurse in the
treatment of addiction disorders and how these nurses are uniquely suited to advocate and
be leaders and lobbyists to influence public policy for this population. The third
manuscript is based on a retrospective chart review of data from 161 pregnant women
with opiate addiction admitted to an inpatient psychiatric facility over a one year period
and describes their treatment needs and prn usage in relation to their disposition at
discharge. The combined information from these three manuscripts will be used as a
blueprint to offer evidence-based practice recommendations for primary care and
psychiatric care providers to enhance their practices with this population.
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Manuscript #1
Pregnancy and Opiate Addiction: A Review of the Literature

1

Abstract

This paper is a review of 12 research articles, published between 1997 and 2014,
which investigate the treatment of pregnant women with opiate addiction. The
significance of the problem of opiate addiction and pregnancy and the resulting neonatal
abstinence syndrome cannot be overestimated. By identifying effective treatment
strategies for this population to treat opiate withdrawal symptoms management and
addiction treatment options, the quality of life for these women and unborn children can
be enhanced.

Keywords: opiates, pregnancy, addiction
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Opiate Addiction, Pregnancy and Treatment Modalities: A Review of the
Literature
The use and misuse of both prescription and illegally obtained opiates has become
an epidemic and costly public health problem among pregnant women in the United
States. Martin, Longinaker, and Terplan, (2014) reported that during the period from
1992-2012, 2% to 28% of pregnant women in the United States sought treatment for
abuse of prescription opioids and that 1% to 19% were admitted for treatment of
prescription opioids. According to the Substance Abuse and Mental Health Services
Administration (SAMHSA) combined data for 2007 and 2008, 5.1% of pregnant women
ages 15–44 reported past month use of illegal drug use which could include abuse of
prescription medications obtained “on the street” (SAMHSA, 2009). The rate of current
illicit drug use of all types in combined data from SAMHSA (2013) was 14.6 percent
among pregnant women aged 15 to 17, 8.6 percent among women aged 18 to 25, and 3.2
percent among women aged 26 to 44.
Treatment options for pregnant women with opiate addictions include
detoxification or drug replacement therapy with methadone or buprenorphine. Regardless
of the treatment approach, withdrawal from opiates is difficult for pregnant women. An
important research question is: Which treatments are available to hospitalized pregnant
women with opiate addiction and what are their options for treatment when discharged
from the hospital setting? Nursing care can be improved and tailored to fit the needs of
the patient population when the effectiveness of current treatment methods are researched
and examined.
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Substance use during pregnancy is associated with harmful effects to both the
mother and fetus. According to Patrick (2012), from 2000 to 2009 the number of
newborns with neonatal abstinence syndrome resulting from the mother’s use of drugs
during pregnancy tripled and the number of mothers using opiates at delivery increased
five-fold from 1.10 to 5.63 per 1,000 births. Jackson and Shannon (2012) report that one
of the most devastating prenatal effects of using opiates is the repeated periods of
intoxication and withdrawal which can result in life threatening complications for the
fetus as well as postnatal complications of neonatal abstinence syndrome.
Opiate addicted pregnant women are a very specific population with specific
needs. Standard of care would necessitate a universal substance use screening during
pregnancy and referral to treatment such as maintenance therapy if warranted. When a
woman is identified as pregnant and opiate addicted, evidence-based practice guidelines
and research recommend referral for short term hospitalization for opiate detoxification,
followed by then treated with methadone or buprenorphine as a safer substitute on a
maintenance basis. However, according to Martin et al. (2014), only about a third of the
women hospitalized when pregnant for opiate addiction are placed on medication assisted
therapy despite the standard of care for opioid abuse in pregnancy. A comprehensive,
standard of care program regimen improves maternal and neonatal outcomes as well as
reduces associated adverse health consequences (Jones, O’Brady, Malfi, & Tuten, 2008;
Kaltenbach & Finnegan, 1998).
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Significance/Morbidity/Mortality
The significance of the problem of opiate addiction and pregnancy and the
resulting neonatal abstinence syndrome cannot be overestimated. The recent trends in
opioid use with women are alarming. The overall rate of heroin initiation increased for
women from 0.06% in 2002-2004 to 0.10% in 2009-2011 (SAMHSA, 2013). There has
been a 50% increase in persons 12 and older who are dependent on heroin from 180,000
in 2007 to 360,000 in 2011 (SAMHSA, 2013). There has been greater than a 500%
increase among women in opioid pain reliever overdose deaths since 1999 with opioid
overdoses surpassing motor vehicle accidents as a leading cause of death (CDC, 2014).
In addition, in the U.S., 25% or more of all pregnant women admitted for treatment report
prescription opioid use (CDC, 2014).
Neonatal Abstinence Syndrome (NAS), which is observed in infants of a mother
who has been using opiates, occurs in 55-94% of exposed infants with medication
required in approximately 50% of the cases (Kahila, Saisto, Kivitie-Kallio, Haukamaa, &
Halmesmaki, 2007). The mean length of stay for infants with NAS is 16.4 days at an
average cost of $53,000.00 per infant (Martin, Longinaker, & Terplan, 2014).
Complications from NAS include dysfunction in feeding, gastrointestinal dysfunction,
autonomic dysfunction, failure to thrive, seizures, low birth weight for gestational age,
and respiratory problems (Martin, et al., 2014). The abuse of heroin or other opiates
during pregnancy is associated with a 600% increase in prenatal obstetric complications
(SAMSHA, 2013). Babies who are born to opiate-abusing mothers have lower birth
weights, and these infants are at greater risk of sudden infant death syndrome (SIDS).
Opiate-abusing mothers tend to have decreased health and poor nutrition, are less likely
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to get adequate prenatal care, and are more likely to abuse other dangerous substances
(SAMSHA, 2013).
The purpose of this paper is to summarize findings from a literature review that focused
on treatment preferences and needs of opiate addicted pregnant women and research on
current treatment. In addition, this paper will examine the gaps in research, and make
recommendations for evidenced based practice to improve the quality of life for this
unique population of women and children.
Review of the Literature
Search Methodology
An integrative review of literature relating to treatment needs of pregnant opiate
addicts was conducted. The online databases used for the search included the Cumulative
Index to Nursing and Allied Health Literature (CINAHL), PsycINFO Psychology
Information, MEDLINE, the Cochrane Database of Systemic Reviews, Article First and
Elsevier. Key words used in the search were pregnant, opiate addicts, users, dependence
and women. In additions, retrieved studies were graded on the strength of evidence based
on the Strength of Recommendation Taxonomy (SORT) criteria (see Annotated
Bibliography).
Inclusion and Exclusion Criteria
Initial inclusion criteria comprised any study that contained information
regarding both opiate addiction in general and pregnant women with opiate addiction and
treatments for this population that met quality and evidence grading standards published
in the 5-year period prior to 2012. The literature was screened to make sure that it
represented the population of opiate addicted pregnant women whenever possible.
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Following this initial review of articles obtained in the search, exceptions were made
because two studies older than the 5-year mark had a strong evidence rating. In addition,
some articles were not excluded even though they addressed opiate addiction as a whole
because they were landmark studies of high quality involving opioid addiction.
Exclusion criteria encompassed studies focused on addiction in general (not specific to
opioids) or the physiological effects on the newborns of addicted women.
Findings
Twelve studies focused on the criteria mentioned above and were included in this
evidence review. The twelve studies can be categorized into studies which focused solely
on opiate addiction and pregnancy from a drug replacement therapy perspective, and
those that investigated both pharmacologic treatment and other factors determined to be
equally important to treatment success.
Treatment Modalities
Drug Replacement Therapy
A significant amount of research has examined the effects of opiate addiction on
the developing fetus and on the infant after birth. In addition a large amount of research
has been completed which favors drug replacement therapy in lieu of detoxification for
the pregnant opiate addicted woman.
The studies focusing on drug replacement therapy for the opiate addicted pregnant
woman recommend either methadone or buprenorphine as the drug of choice to prevent
opiate abuse in women during pregnancy. Some researchers conclude that methadone is
superior while others claim buprenorphine is, yet some state either will be equally
efficacious.
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In an example of a study that recommends methadone as the drug of choice,
Burns, Mattick, Lim, and Wallace (2007) reported on a systematic review of descriptive
studies using record linkage in the U.S. There were 2993 births to women on methadone
at delivery; these increased from 62 in 1992 to 459 in 2002. The authors concluded that
continuous methadone treatment during pregnancy was associated with earlier antenatal
care and improved neonatal outcomes. Early engagement in methadone treatment by
pregnant women with opiate addiction was identified as essential. Study limitations
include the fact that due to the cross sectional nature of the reviewed studies cause and
effect could not be determined. The study controlled only for confounding variables on
main neonatal outcomes and future work would need to examine relationships between
variables in more detail. Another limitation is that the study did not have information on
methadone dosage or treatment policies, critical knowledge affecting retention and
outcomes.
Another study, which supported methadone maintenance, was a Cochrane
systematic review of multiple randomized clinical trials among opiate addicted
individuals in different countries by Mattick, Breen, Kimber, and Davoli (2009). This
study, although not specific to pregnant women was included because of its significance
and the large number of subjects (n=1969). The authors found that methadone
maintenance treatment had superior treatment effectiveness as compared to treatments
that did not involve opioid replacement therapy such as detoxification, drug rehabilitation
or placebo medications. In this study, methadone maintenance treatment was shown to
retain patients in treatment, which is considered paramount to treatment effectiveness.
The theme of treatment retention was prevailing in the studies for success of treatment.
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However, a retrospective case series study of 23 infants born to 22 pregnant
women in the U.S. by O’Conner, Alto, Musgrave, Gibbons, Llatno, and Karnes (2011)
found that buprenorphine was the best available practice for opioid dependent pregnant
women and the early identification and treatment of this at risk population is essential to
reduce complications and decrease withdrawal for the neonate. In agreement with the
O’Conner et al.’s (2011) study, Kahila, Saisto, Kivitie-Kallio, Haukamaa, and
Halmesmaki (2007) conducted a case-control study among 66 pregnant women in
Finland and buprenorphine was again found as the preferred treatment option for opioid
addicted pregnant women. This study mentioned that drug replacement therapy such as
the use of buprenorphine prevents relapses, raises social status of the women and helps
avoid infectious disease transmission, overdose death and criminality associated with
street drugs. Their findings also state that it improves overall maternal health and life
circumstances and thus decreases the risk to the fetus.
An earlier high quality RCT performed by Mattick et al. (2002) with a sample of
405 opioid dependent subjects in the U.S., found that both methadone and buprenorphine
were effective in treating opioid dependence by producing significant reductions in drug
use. Changes in well-being and social functioning were also noted as significant.
Drug Replacement and a Holistic Approach
Studies involving treatment interventions reiterated the importance of drug
replacement therapy but suggested that something else was needed for treatment success.
In a review of opiod dependence among pregnant women in different countries, Unger,
Metz, and Fischer (2012) found that using opioid agonist maintenance treatment was the
best option for the majority of women, noting that few opioid addicted women could
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handle abstinence from opioids. They mention that treatment, however, should involve
more than just replacement therapy and should be an interdisciplinary team approach that
includes social workers, nurses, psychologists, psychiatrists, gynecologists,
anesthesiologists and pediatricians. They also recommend the treatment of comorbid
psychiatric conditions and addressing the financial, legal and housing aspects as well as
offering psychosocial support. A review of the literature by Veilleux, Covlin, Anderson,
York, and Heinz, (2010) reiterated the need for psychosocial interventions and
specifically mentioned outreach counseling and brief outpatient therapy to decrease
relapse and retain the individuals in treatment. In a case series study in the U.S. by Jones,
Martin, Heil, Kaltenback, Selby, Coyle, Stein, Arria, and Fischer (2008), the study
authors stated that the optimal treatment approaches for opioid dependent pregnant
women should be tailored to the needs of each patient and such tailored treatment needs
to be further investigated. Jones et al. (2008) also noted that opioid dependent pregnant
women face huge stigma from family and society and that health care providers can
mitigate this source of stress by directly addressing the patient’s fears, guilt and treatment
resistance.
Lack of Treatment Accessibility
In a case review study of 420,665 cases in the U.S., Martin et al. (2014) looked at
recent trends in treatment admissions for prescription opioid abuse during pregnancy. A
significant finding in this study was that only a small proportion of the women with
opioid addiction were receiving medication-assisted therapy. The researchers note that
mediation-assisted therapy is the standard of care for opioid dependent pregnant women,
indicating that it leads to improved maternal medical status, decreased fetal morbidity
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and increased utilization of prenatal care. The authors attribute the lack of access to the
medication-assisted therapy, stating that only 9% of substance abuse treatment facilities
in the US offer medication-assisted therapy (Martin et. al, 2014).

Gaps in literature
There is a plethora of research supporting the use of drug replacement therapy in
opiate addicted individuals (Mattick et al., 2006; O’Conner et al., 2011; Kahila et al.,
2007; Mattick et al., 2009; and Veilleux et al., 2010). These same studies give scientific
support for the use of opioid replacement therapy in opiate addicted pregnant women.
The gaps in the literature involve the following questions:
1) What is the preferred method of treatment for opiate addicted pregnant women when
identified as pregnant, detoxification from opiates or drug replacement therapy? Do they
prefer buprenorphine or methadone if they prefer drug replacement therapy?
2) Why are women not being offered drug replacement therapy when pregnant and
opiate addicted if it is known to be the standard?
3) What type, if any, of comprehensive approaches to treatment have shown to achieve
long-term effects with this vulnerable population?
Implications for Future Research
The research included in this review suggests that drug replacement therapy is the
standard in treatment for opioid addicted pregnant women. Some research further
suggests that giving methadone or buprenorphine alone is inadequate. Rather, many of
the researchers point out that there is a need for a multidisciplinary approach beyond drug
replacement therapy to create lasting change and make a difference in the lives of the
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women and newborn children. Perhaps longitudinal studies of these women and their
children would provide a blueprint and help guide clinicians further in other areas that
could promote increased quality of life for the women and children.
Nursing Practice Change Recommendations
According to Young, Borden and Shea (2014) in their webinar presentation on
treatment needs for opiate addicted mothers in the U.S., barriers to best practice for this
unique population include: 1) the variation in the child welfare response, 2) the lack of
medication availability, 3) the lack of collaboration between social services, healthcare
professionals, state, local agencies and law enforcement, 4) the lack of sufficient
comprehensive, long term treatment for women and their children and5) the knowledge
and practice gaps in best practices in screening and assessment of addiction in pregnancy,
post pregnancy, and neonatal abstinence syndrome.
Advanced practice nurses are in a unique position to assist in the development and
implementation of this type of collaborative approach, in which a team would develop a
plan to identify women with opioid use during pregnancy and engage them in prenatal
care, medical care, substance use treatment and other needed services, (AACN DNP
Essentials, 2006). This approach is believed to reduce the number of crises at birth for
women, babies and the system (Young et al, 2014).
Conclusion
There are immediate benefits of opioid replacement therapy for pregnant women
addicted to opiates. Through treatment with either methadone or buprenorphine, the
woman is able to remain off unsafe street drugs and health risks to the unborn child are
reduced, although neonatal abstinence syndrome is still likely. The risk to the fetus and
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mother is reduced as indicated by several groups of researchers who have explored the
topic (Mattick et al. 2009; Kahila et al. 2007; Martin et al. 2014). Further research is
needed to help determine what would enable pregnant women addicted to opiates to
remain off of street drugs and enhance her ability to remain drug free. Further studies on
what constitutes effective lasting treatment and that would have long-term positive
impact on the lives of the women and their children would be optimal.
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Implications

Evidence Level

Level 1, high quality RCT

Grade

Grade A

19

Author/Year/Journal/Title Unger, A., Metz, V. & Fischer, G./2012/Obstetrics and
Gynecology International/Opioid dependent and pregnant:
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and at risk of adverse pregnancy outcomes and perinatal
complications. Opioid agonist maintenance treatment is the
best option for the majority of women. Few opioid addicted
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among opioid dependent populations.
Treatment retention is extremely important in successful
outcomes with opioid addiction. Two psychosocial
interventions, outreach counseling and brief outpatient
therapy plus contingency management resulted in lower
relapse rates and higher treatment retention at baseline.
Further research on psychopharmacological medications is
needed.
Many treatment options for opioid dependence are available
and many work fairly well. Opioid addiction, however, is
found to be chronic and unrelenting and often people drop
out of treatment which exposes them to an at- risk lifestyle
and decreased quality of life. Hopefully generalizing the
outcome research to real patient outcomes will assist in
combating this addiction.
Level 3, Expert Consensus

Grade

Grade C

Purpose of Article

Findings

Implications
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Author/Year/Journal/Title Pritham, U., Paul, J. & Hayes, M./2012/Association of
Women’s Health, Obstetric and Neonatal Nurses 41, 180Reference Information
190/Opioid dependency in pregnancy and length of stay for
neonatal abstinence syndrome
Type of Literature/Design Retrospective descriptive study

Sample

152 opioid dependent pregnant women

Purpose of Article

To examine opioid replacement therapy in pregnancy and
neonatal outcomes, length of stay for neonatal abstinence
syndrome.

Findings

Evidence Level

Replacement therapy with either methadone or
buprenorphine maintenance therapy caused prolonged
hospital stays for neonates. Breastfed neonates had shorter
length of stay. Prenatal exposure to methadone caused
longer length of stay for neonate than infants with prenatal
exposure to buprenorphine.
Harm reduction strategies for opioid dependent pregnant
women should include guidance on daily treatment doses
and recommendations to avoid concomitant use of benzos in
order to lessen neonatal abstinence syndrome.
Breastfeeding should be recommended. Understanding
perinatal and neonatal outcomes of pregnant women on
replacement therapy will help identify optimal treatment for
opioid dependency with pregnancy.
Level 2

Grade

Strength C

Implications

23

Author/Year/Journal/Title Crome, I., Khaled, M.K.Ismail, Ghetau, E., McAuley, R.,
Bloor, R., Jones, P. & O’Brien, P.M.S./2005/Drugs:
Reference Information
Education, Prevention and Policy 12 (6) 431-436/Opiate
misuse in pregnancy; finding of a retrospective case note
series
Type of Literature/Design Retrospective Case Series

Sample

50 pregnant opiate addicted women

Purpose of Article

Evidence Level

To identify the obstetric and neonatal characteristics of highrisk pregnancies of opiate addicts, the level of contact with
the offered service and the relationship between level of
attendance in the service and pregnancy outcome.
Birth weights of 27 of 39 babies in the study were < or =
to10th percentile for gestational age. Positive association
between attending the treatment services offered at least
70% and birth weight. Retention in treatment is associated
with improved outcomes in pregnant drug users.
Participation in treatment programs for opiate addiction may
give the stability needed in the life of an opiate addict. It
gives them the opportunity for substitution medication and
also helped to resolve housing, employment and other social
issues. A program of research should be developed to
examine the impact of maternal drug use on the children at
birth to adolescence and evaluate interventions aimed at
improving their health and well-being both short and long
term.
Level 3

Grade

Grade C

Findings

Implications

Problem with study is that it is difficult to draw conclusion
based on retrospective analysis of relatively small sample
size.
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Author/Year/Journal/Title Martin, C., Longinaker, N., Terplan, M. /2014/Journal of
Substance Abuse Treatment/Article in Press retrieved from:
Reference Information
http://dx.doi.org./10.1016/j.jsat.2014.07.007. Recent trends
in treatment admissions for prescription opioid use during
pregnancy
Type of Literature/Design

Case Review via TEDS Admissions Data

Sample

420,665 cases reviewed

Purpose of Article

Examine trends in opioid pregnant women treatment
admissions

Findings

Overall there were 420,665 substance abuse treatment
admissions from 1992 to 2012. Among pregnant admissions
the proportion reporting any abuse of opiates rose from 2%
in 1992 to 28% in 2012.

Implications

Evidence Level

The small amount of opioid admissions receiving
medication-assisted therapy is alarming. The demand for
treatment of prescription opioids during pregnancy has
increased in recent years parallel to the increase in abuse
among the general population. As opioid abuse increases
there is a need for increase services with a multidimensional
approach to preventing its impact
Level 2

Grade

Strength B
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Abstract

This paper explores the role of the Advanced Practice Nurse in the treatment of
addiction at the policy making level. By using the strengths inherent in the Advanced
Practice Role such as advocacy, leadership and lobbying, the DNP graduate can shape
policy to create change. Policy change is explored through the Kingdon Conceptual
Framework. The problem of opiate addiction in Kentucky is examined and current
attempts to change the State legislative policy for the treatment of opiate addiction is
presented with emphasis on the difference the Advanced Practice Nurse can make in
implementing change.
Keywords: opiates, Naloxone, policy
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The Role of the Advanced Practice Nurse in the Treatment of Addiction Disorders:
Advocacy, Leadership, Lobbying to Influence Public Policy
Epidemic increases in the use of opiates and heroin throughout Kentucky are
consistent with opiate use trends in the United States as a whole (Substance Abuse and
Mental Health Services Administration [SAMHSA], 2010). In addition, increased use
has contributed to increased deaths from heroin and opiate overdose in the past decade.
This paper explores how advanced practice nurses can influence the treatment of
addiction in the policy arena by taking on the roles of advocate, leader and lobbyist. One
such way would be to help facilitate policy that would mandate the availability of
Medicaid funding for inpatient opiate addiction treatment and increase the availability of
naloxone to address the problems of opiate addiction and heroin deaths. In this paper, the
policy perspective for opiate and heroin addiction problems will be analyzed using
Kingdon’s multiple streams theory. A case study involving the introduction of Senate
Bill 5, which involved increasing the availability of naloxone to overdosed heroin
substance abusers and increasing treatment options to this population, and was
unsuccessfully presented before the Kentucky legislature in the spring of 2014, will be
highlighted.
Background and Significance of Opiate Addiction Problem
Opiate drug abuse costs lives, affects the health of newborn infants born to
abusing mothers and has a negative impact on epidemic numbers of individuals in the
United States (SAMHSA, 2010). The Network for Public Health Law (2014) states that
fatal drug overdoses haves increased six-fold over the past three decades with 15,000 of
these deaths attributed to opiates alone. In 2010, The Centers for Disease Control
estimated that over 78% of drug overdoses were unintentional, and those that were opiate
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induced could have been prevented by an opioid antagonist such as naloxone. Opiate
overdose can be easily and inexpensively reversed through the timely administration of
naloxone and emergency care (Wermerling, 2010), yet access to naloxone is limited due
to laws and regulations that predate the overdose epidemic era.
The problem exists on a national scope as well as statewide. According to
Kerlikowske (2012), drug induced deaths are the leading cause of injury death in the
United States. A 2009 SAMHSA report on substance abuse suggests that 19% of women
ages 15 to 44 are addicted to opiates. These data are critical when viewed within the
context of consequences for women of childbearing age. According to Patrick (2012),
from 2000 to 2009 the number of newborns with neonatal abstinence syndrome resulting
from the mother’s use of drugs during pregnancy tripled and the number of mothers using
opiates at delivery increased fivefold from 1.10 to 5.63 per 1,000 births.
Opiates, including prescription drugs, are the most commonly used drugs among
primary drug treatment admissions in the state of Kentucky (SAMHSA, 2012).
According to the Office of National Drug Control Policy (2012), Kentucky was one of
the top ten states for rates attributed to non-medical use of pain relievers among persons
aged 12-17. Reports for 2010-2011 indicated that approximately 161,000 Kentuckians
ages 12 and older used pain relievers for non-medical reasons (SAMHSA, 2012).
Overdose deaths attributed to the use of heroin accounted for nearly one-fifth, or 19.56%,
of all Kentucky Medical Examiner drug overdose cases in 2012. In 2011 the rate was
3.22%. Of the 1,004 overdose deaths in 2011, 888 were found to be unintentional (Office
of Drug Control Policy, State of Kentucky, 2012).
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Addressing the Problem: Advanced Practice Nurse Responsibilities
“Health policy influences multiple care delivery issues, including health
disparities, cultural sensitivity, ethics, the internationalization of health care concerns,
access to care, quality of care, health care financing, and issues of equity and social
justice in the delivery of health care” AACN (2006, p. 13). According to the Institute of
Medicine’s hallmark 2001 report, DNP graduates are “prepared to design, influence, and
implement health care policies that frame health care financing, practice regulation,
access, safety, quality and efficacy” (AACN, 2006, p. 13). DNP graduates are especially
capable, according to the AACN (2006), of addressing issues of social justice and equity
in health care due to their powerful practice experience, which can translate into strong
influence on policy formation. Thus DNP-prepared nurses are able to integrate their
experience into effective action in the policy arena and help their patients receive access
to care and equity in care. According to Goudreau and Smolenski (2013), advanced
practice nurses “are already taking action to create better practice environments and
conditions, investigating how they can work to define positive change for their patients/
clients, and how they can have an impact on the health of communities and the nation
through the health policy process” (p. 305).
The Advocate Role of the APN in Opiate Addiction Treatment
Nursing as a discipline tends to resist political involvement; many nurses prefer to
focus on helping patients directly. Lobbying in particular has developed a bad
connotation and nurses historically avoid it. According to Hall-Long (2009) in her
article on nursing and public policy, nurses will get involved to a point but are still not as
actively involved in the legislature as many other health professionals. However, as
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nurses enter into advanced practice, they are beginning to understand that sometimes
taking care of a patient means serving as patient advocates, which may encourage them to
leave the bedside comfort zone and venture into the political arena. Nurses can draw
upon the bedside experience to influence public policy to better serve the needs of the
patients they wish to help (Maryland & Gonzalez, 2012). According to Maryland and
Gonzalez (2012), nurses can influence public policy through advocacy by providing real
life examples to illustrate the needs of patients and the outcomes of public policy on
patient morbidity and mortality. Nurses can advocate for increased access to care, which
is certainly needed in the case of the patients who are addicted to opiates.
There is a lack of services available to those with opiate addiction, a lack of
treatment facilities and a lack of access to emergency measures such as naloxone to
families and non-physicians, despite the fact that these individuals are most likely to
come into contact with an individual who has overdosed. Since healthcare costs, access
and quality outcomes are a large part of many political agendas, the nurse is in a perfect
position to influence these agendas due to the inherent trust the public and patients have
in the nursing profession (Maryland & Gonzalez, 2012). “When nurses have the ability
to share experiences and insights with public and elected officials, they can advocate for
patients and families effectively and become a powerful force in the policy-making
process” (Maryland & Gonzalez, 2012, p.2).
The Leadership Role of the APN in Opiate Addiction Treatment
The APN leadership role in health policy can be effective at an individual level or
through groups of APNs who share a common interest or goal in patient outcomes.
According to Filipovich (2013), “Leadership in any form requires current knowledge of
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the issues that affect nursing and health care as well as how policy decisions pertaining to
those issues are made” (Kindle Locations 3746-3748). The APN is ideally positioned to
take a leadership role in policy due to the knowledge base required at that level of
practice. In the case of opiate addiction, effective advocacy on the part of the APN
requires assuming a leadership role and knowing effective strategies to promote
legislation that would increase treatment options for those addicted to opiates. Assuming
a leadership role would mean organizing efforts to lobby politicians, creating a coalition
to fight for the increased treatment option availability for addicts and organizing the vast
scientific research that backs the efforts of increasing naloxone availability to families of
people addicted to opiates and emergency personnel that come into contact with the
overdosed individual. The APN has the expertise needed to spearhead efforts to teach
family members about the safe administration of naloxone, as well as prevention,
treatment and aftercare of an overdose.
Advanced practice nurses make ideal leaders because they are educated for a
political journey, according to Hall-Long (2009). She asserts that the skills she gained
from her nursing education, such as communication, advocacy, listening, problemsolving, and reflection, have proven to be essential in times of political compromise.
These skills have made her an effective leader who eventually became a Delaware
legislator. Nurses are excellent communicators, listeners and multitaskers and receive a
high level of public respect, positioning them effectively in leadership.
The Lobbyist Role of the APN in Opiate Addiction Treatment
According to Milstead (1997), the clinical expertise of APNs translates well into
the political arena. Milstead (1997) states that bringing a problem to the attention of the
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government is often the first step in solving it. APNs can use their expertise to provide
fact sheets, statistics and personal experiences to bring a problem to the attention of
legislatures (Milstead, 1997). APNs have expert knowledge to share and are skilled at
synthesizing the available research on a topic in order to lead an evidence-based
discussion of the issue. APNs know how to tap into available resources within
communities, and they know what services are available and needed. APNs can look at
the multifaceted scope of a problem and approach it from an evidence-based perspective.
In reference to opiate addiction the APN is able to share the experiences of treating those
with opiate addiction and provide the statistics on relapse, lack of treatment resources and
mortality rates due to overdose. In addition to evidence, the APN can provide personal
experiences with individuals with opiate addiction who want to detoxify from opiates but
have neither the willpower to do so on their own nor the money for a private drug
rehabilitation treatment facility. The APN can share the stories of families who worry
daily whether they will find their son or daughter dead from a heroin overdose and who
would have some relief if they had naloxone on hand to administer in an emergency.
Conceptual Framework
Kingdon (2012) developed the streams metaphor to describe how issues become
part of policy-making agendas, emphasizing that this occurs when the problem, policy
and political streams merge at the same moment, thus creating a window of opportunity
for change to occur. The problem stream describes the issue or problem at hand. It
involves the process of persuading those in power to view a certain problem as the one
that should get their attention at a specific time when there are always competing
problems for the agenda. It also involves convincing lawmakers that the problem can be
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reduced or eradicated by the policy presented instead of the other solutions or alternative
approaches. According to Kingdon, the policy stream encompasses all possible solutions
to the problem that the lawmakers could pursue within the timeframe and political
climate present. Within that climate, Kingdon observes that streams converge and may
create a window of opportunity for a policy to become a law. Strategies include focusing
events in order to bring problems to the public forefront, thus making it an issue that is
ripe for the “window of opportunity” (Kingdon, 2011). Heroin overdose and opiate
addiction are reaching epidemic proportions and overdose deaths of celebrities bring the
issue into the public eye; thus the problem is being brought to the public forefront. Now
may be the perfect time for APNs to offer solutions to the problems and to lobby for
increased treatment options and access to treatment for opiate addicts.
Kingdon’s Streams Model (Figure 1)
Problem Stream
Window

Policy Stream
of

Politics Stream
Opportunity

TIME

34

Application of Kingdon's concepts to promote policy change requires a clear
understanding of the problem of opiate addiction and how it came about in the United
States.
The Problem of Opiate and Heroin Addiction
Historical Perspective
Opiate addiction originated in this country around the time of the Civil War
(Courtwright, 2001). Why then? Around 1840 New Englanders brought the first 24,000
pounds of opium into the United States. Since then, the face of opiate addiction has
changed many times in the populations affected, prompting a response from the country’s
social, political, legal and medical communities (Courtwright, 2001). Opioid addiction
has been primarily viewed through two different lenses: (1.) it is an incurable disease
requiring long term maintenance with drug replacement therapy and (2.) it is caused by a
personality flaw or lack of moral character and is best treated by abstinence or by
punitive measures in the criminal justice system. Stigma and empathy toward people
addicted to opiates have waxed and waned depending on the population most affected.
For example, in the late nineteenth century an estimated 300,000 persons with opiate
addiction were mostly either female upper class or disabled war veterans, thus this
population was treated with empathy (Courtwright, 2001). The population changed,
however, with the introduction of heroin as a “cough suppressant” and injectable forms of
drugs which contributed to increased use among street criminals, changing the attitude of
empathy to one of disdain and stigma (Courtwright, 2001).
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Post World War II, the population of those with opiate addictions shifted to the
inner city ghetto areas and the attitudes toward this population seemed to shift towards
stigmatization and further away from empathy. During the subsequent period, 1960-1980,
approximately 500,000 Americans of all social and economic backgrounds used opioids,
thus creating a major medical problem and a social “hot button” topic (Courtwright,
2001). According to SAMHSA data on drug use for 2012 approximately 898,000 people
in the United States were using heroin, treatment admission rates for addiction to opioid
analgesics more than doubled between 1992 and 2001, and emergency room visits related
to opiate abuse increased 117 percent between 1994 and 2001 (SAMHSA, 2012).
Some medical problems are more prevalent in people addicted to opioids than in
the general population. Many of the problems include infections that can be life
threatening, such as cellulitis, wound botulism, necrotizing fasciitis, and endocarditis.
Diseases that are transmissible pose serious public health threats, such as HIV/AIDS,
hepatitis, syphilis, and tuberculosis (TB). Many patients in medication-assisted treatment
(MAT) for opioid addiction have chronic diseases such as diabetes, asthma, or
hypertension, as well as conditions such as severe dental problems or seizure disorders,
which may have been neglected or poorly managed for years. Some patients have chronic
obstructive pulmonary disease (COPD), hypertension, coronary artery disease, or other
illnesses related to long-term heavy tobacco use. Management of chronic pain for patients
in MATs is particularly challenging because of the role of opioids in pain treatment. In
addition, opioid intoxication may result in head trauma or other bodily injury. Criminal
activity may produce severe physical injuries such as gunshot wounds.
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While methadone, buprenorphine and naltrexone are all used to assist with
treating the chronic addiction to opiates, there still remain issues with lack of access to
these treatment options. Moreover, current public opinion still vacillates between
blaming those with addiction and following a punitive approach versus recognizing
addiction as a disease to be treated. As Olsen and Sharfstein (2014) point out, “First, the
understanding of opioid use disorder as a medical illness is still overshadowed by its
misconception as a moral weakness or a willful choice” (p.1393). Even in the substance
use treatment community, many still believe that recovery depends solely on the
willpower to abstain from all opioids, including methadone and buprenorphine (Olsen &
Sharfstein, 2014). Furthermore, many treatment facilities require those who receive drug
replacement therapy to taper off or discontinue and detox to be considered a success at
treatment (Olsen & Sharfstein, 2014). As such, “Reimbursement for treatment may cover
only the most basic services, including medication delivery and a weekly professional
encounter” (Olsen & Sharfstein, 2014, p. 1394). Since opiate detoxification is not
considered life threatening, most insurance companies and hospitals refuse patients based
on the sole admitting diagnosis of opiate detoxification. Moreover, the patient usually
has to have suicidal ideation or a co-morbid condition for admission. Olsen and
Sharfstein (2014) have also noted that the language used to describe opiate addiction is
stigmatizing. For example, the active user is called “dirty” while those who are not using
are described as “clean.” “Junkie” is still a popular term to describe both opiate and
heroin addicts (Olsen & Sharfstein, 2014).
The history of how opiates came into the country and how they created the
opportunity for addiction across all socioeconomic spectrums is fascinating. Next,
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Kingdon's model recommends an examination of possible solutions to the problem of
opiate addiction within the present timeframe and current political climate to determine
the likelihood of the three streams converging to create the window of opportunity
(Kingdon, 2007).
The Policy of Opiate and Heroin Addiction
Application of the Kingdon policy stream concept calls for exploration of all
potential solutions to the problem that are available to decision makers (Goshin & Byrne,
2009). Therefore, it is important to begin the exploration by recognizing that opiate
addiction is typically viewed as either a medical illness or disease and treated with
interventions or it is viewed as a moral weakness with incarceration. If treated, four
options are generally available: detoxification, methadone maintenance, buprenorphine
replacement therapy and naltrexone (aversion therapy). However, due to lack of
insurance coverage and lack of availability of treatment facilities available to those
without funds, these treatment options may not necessarily be available to those who are
addicted to the drug. Legislative efforts can address the problem, and the APN is in a
position to help enact effective legislation to help the treatment of those with opiate
addiction.
Legislative approaches
Senate Bill 5 is an example of a recent legislative approach in the state of
Kentucky to increase the treatment options available to those with opiate addictions.
Although legislation is not intended to completely resolve the problem, it is an important
approach for easing the burden of opiate overdose in Kentucky. In addition, it addresses
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an important public issue related to the hundreds of fatal heroin overdoses in Kentucky
during the past three years as well as the crimes committed by those suffering from
heroin addiction, for the money required for their drugs. The proposal for the bill
included use of Medicaid programs in the state to cover several inpatient and outpatient
options for people with opiate addiction and it encompassed heroin and prescription drug
abuse problems as well. The bill specified expansion of treatment programs for the opiate
addicted population because Kentucky currently has only about 2,400 treatment beds for
those addicted to substances. The deficit in available treatment beds results in wait lists of
six months or longer for treatment – a time frame that is untenable for those who need
help. Senate Bill 5 also sought to increase the availability of naloxone and make it
available to families of those with addictions and emergency workers.
Treatment options
Methadone is a limited treatment option because it is only available through
specialized treatment clinics (National Institute of Health, 2010). Also, use of
methadone replacement therapy is often met negative opinions and stigma. Patients
undergoing this treatment may be made to feel that they are just replacing one drug for
another, that they are somehow morally, physically, or spiritually weak for not being able
to be completely free of all substances. Another option is buprenorphine which is used
for detoxification and relapse and does not require inpatient admission. Two types of this
medication exist. Suboxone (buprenorphine), gives the euphoria and feeling of wellbeing similar to the abused drug of choice but at a safe prescription level and dosage,
simultaneously blocking any opiate receptors in case the patient were to use opiates while
on the drug. Subutex, is purely an opiate agonist which does not give the euphoria or
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feeling of well-being. Therefore, subutex is often favored as the drug to give, yet those
with addictions are often not as adherent with this therapy. Naltrexone is an opioid
receptor blocker that not only blocks heroin overdose but in the depot injection form of
Vivitrol® can be effective for long periods, diminish opioid use, reduce craving and
promote patient adherence to treatment (National Institute of Health, 2010). However,
Vivitrol® is expensive and therefore cost prohibitive to a large percentage of those with
addictions.
The Politics of Opiate and Heroin Addiction
The politics stream involves the political climate and the public opinion about the
issue and policy solution being presented. With the current administration, Kingdon’s
window of opportunity on a national level is wide open. The window was open
nationally for a bill like Senate Bill 5 to be successfully passed, but would it be in the
state of Kentucky? According to Schambra (2009), “Both his ambition and his unique
style of issue management show that Obama is emphatically a policy approach president”
(p.127). Schambra (2009) states that Obama’s policy approach looks at long term
problems of healthcare, taking into account the whole and avoiding attempts to solve the
problem in small pieces. Obama has demonstrated an approach to the national drug
problem by looking at objective evidence, scientific facts and expert counsel by the
formulation a Nation Drug Control Strategy in 2010.
On a national scale, the Obama administration has attempted to change drug
abuse treatment and perspective through development of new policy based on scientific
research instead of ideology in his administration. The 2013 National Drug Control
Strategy emphasized that government policy has shifted from that of incarceration
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focused solutions to a drug prevention approach incorporating strategies informed by
science, research and evidence. The strategies emphasize prevention instead of
incarceration. The strategy also empowers health care professions to intervene early
before a condition becomes chronic thus creating access to treatment a reality. In
addition, the strategy gives a voice to those in addiction recovery, and reinforces the idea
that the United States cannot arrest and incarcerate its way out of a drug crisis. Rather, it
views drug issues as being a global problem in “the spirit of shared responsibility”
(Office of National Drug Control Policy, 2012).
Political viewpoints
Two political viewpoints on drug addiction that are prevalent in America today.
One viewpoint maintains that addiction is a disease that needs to be treated with
prevention, education, medical intervention and rehabilitation efforts. In contrast, the
other view is based on personal responsibility and the idea that addiction is a path chosen
by persons who lack fortitude or character. Some politicians argue that if drug use is a
voluntary activity in which the risk is known, then responsibility falls on the person
engaged in the activity (Winkler, 2002). These same individuals would argue that the
government should not put money and effort into treatment for the opiate and heroin
addicted population.
Policy Options and Outcomes
The political climate in Kentucky regarding opiate addiction is favoring treatment
for those with addictions through drug replacement therapy combined with rehabilitation
efforts. In an editorial for the Lexington Herald-Leader, Eblen (2008), pointed out that
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more than 375,000 Kentuckians need drug or alcohol treatment. He argues that for an
investment of $1 spent on treatment, $7 is saved in health care and criminal justice costs.
One could try other options such as legislation that would mandate drug testing before a
patient receives Medicaid, disability or other governmental assistance; yet it would likely
fail because it would be extremely costly to enforce. Another option could be promotion
of abstinence in the school systems as a preventative measure. However, previous Just
Say No campaigns have not proven to be effective in curbing the appeal of drugs
(Rosenbaum, 1998). One could also continue the current approach of prosecuting the
drug dealers, especially in areas where the drug abuse problem is rampant. However, that
approach does not appear to be working at this time. According to Kleiman (2001),
“Neither current drug policies nor current correctional policies offer any real hope of
substantially reducing drug consumption by user/offenders” p. 171. Other options
include incentives to those addicted who remain drug free, which is what was done with
some success in a study of pregnant opiate users by Svikis, Lee, Haug, and Stitzer (1997),
but that would not be cost effective and again, it would be difficult to enforce.
Case Study: Senate Bill 5
The legislation proposed for enactment of Senate Bill 5 would have furthered the
goals of the current National Drug Control Strategy. For example, Senate Bill 5 would
have amended current legislation and redirected a portion of the recaptured savings from
criminal justice reforms be directed to funding of treatment programs for those suffering
from opiate addiction. It would have created a new section of Kentucky Revised Statute
(KRS) by specifying that controlled substance treatment services be offered under
Medicaid and would thus increase treatment availability to opiate addicted populations.
42

It would have also amended the current KRS 217.186 by allowing for the availability of
naloxone for use as a rescue drug for narcotic overdose situations. This would save lives
in the case of overdose emergency situations and create a safe harbor by enacting a new
section of KRS Chapter 218A to provide immunity for persons seeking emergency help
in drug overdose situations.
The goals proposed by Senate Bill 5 would have moved away from a punitive
approach of opiate drug addiction toward a recovery based treatment modality based on
the evidence of scientific research as the most effective approach in the treatment of
addiction. Furthermore, goals of the bill were consistent with the National Drug Control
Strategy set in 2010, which based its strategy on scientific research and inquiry.
Senate Bill 5 did not garner sufficient votes to be passed into law. An apparent
filibuster in the Kentucky House in the final hour of the General Assembly session
prevented it from passing. The three streams converged and the “window of opportunity”
seemed to be conducive to the possibility of passing the bill. The concepts contained
within the bill are still valid, worth reconsidering and fighting for by APNs interested in
promoting treatment options and decreased mortality rates for opiate-addicted
individuals.
Conclusion
The problem of opiate drug addiction and death from overdose will require a
comprehensive solution that will include input and a multidisciplinary approach from
healthcare providers, policy makers, public health officials, law enforcement and
legislators. However, much evidence suggests that an effective strategy to reduce the
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number of deaths from overdose is to remove the legal barrier to obtaining naloxone
(Wermeling, 2010). The APN is in the position to advocate for families of those with
addiction themselves, to provide some relief from worry. The “window of opportunity”
appears to be ripe for the APN to lobby on behalf of this vulnerable population and save
lives.

Addendum from Senator Stine
Sponsor of Senate Bill 5
When asked if she was going to pursue this issue the next legislative session she
responded with this email:
“ Thank you for your email about last session’s SB5. I am not running for reelection so I will not be a member of the Senate when it convenes in January because
my present term will have ended at the end of 2014. In these last days of my term I
have been traveling around the state visiting treatment centers, community leaders
and law enforcement officials trying to raise consciousness about the real threat that
heroin poses to our state. It is a tragedy that the House chose to ignore this
important legislation until the last day of the session and then load it down with
“ripper” amendments so that they ran out of time and failed to pass SB5 in the
session. Please encourage your legislators in your part of the state to take action.
Unfortunately people are dying due to this inaction. If this many lives were lost due
to some unknown virus or natural disaster there would be a huge response and
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outcry. Why are blind eyes being turned toward the heroin epidemic and its terrible
cost in Kentucky lives?
Thanks again for contacting me.”
Senator Katie Stine
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Effective Inpatient Treatment Methods for Opiate Addicted Pregnant Women:
A Retrospective Chart Review Study
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ABSTRACT

This paper explores the treatment needs of opiate addicted pregnant
women by assessing their preferred method of treatment when hospitalized on an
inpatient behavioral unit at a large medical center in a southeastern state of the United
States. The period of assessment was a one year time frame and the study is a
retrospective case review of charts from 161 patients who were hospitalized at that time.
The research questions to be answered included what is the preferred method of treatment
for opiate addicted pregnant women when they are initially hospitalized and how is
frequency of prn usage during treatment associated with their disposition at discharge?
Findings from this study may initiate discussions on what retains a patient in treatment,
what is important to do for the patient while in treatment, and what could be the longterm treatment needs to maintain drug abstinence and improve quality of life.
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Problem Statement
Opiate addiction among pregnant women is a national epidemic that has risen
sharply since 2000 (Patrick, 2012). The number of newborns with neonatal abstinence
syndrome (NAS) defined as the withdrawal syndrome of the newborn of an opiate
addicted mother, tripled between 2000 and 2009 and the number of mothers using
opiates at delivery increased five-fold (Patrick, 2012). Additionally, maternal opiate use
at the time of delivery in the United States increased from 1.19 to 5.63 per 1,000 births
during the years 2000 to 2009 (Patrick, 2012). The costs of treating NAS in 2009 was
720 million dollars; 77.6% of this cost is paid by state Medicaid programs (Patrick,
2012).
According to Stone (2015), pregnant women who misuse substances are
positioned at the center of public health and criminal justice intervention. “The impact of
their substance use on their personal health and the health of their fetuses is a public
health concern, as professionals in this field are dedicated to improving maternal and
infant health” (Stone, 2015, p. 1). This places the woman at a disadvantage since as she
is subject to criminal prosecution, increased surveillance, loss of custody of her child, and
prosecution if she seeks assistance for her addiction issues and is an active user.
The overall goal of this Doctor of Nursing Practice (DNP) program practice
inquiry project was to determine the most effective inpatient treatment methods for opiate
addicted pregnant women. The immediate objective was to conduct a retrospective chart
review of previously hospitalized opiate addicted pregnant women to ascertain the
treatment preferences of the women and to see if there was a correlation in prn usage and
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disposition at discharge. This type of analysis has the potential to help clinicians create a
blueprint for effective treatment of this special population and thereby increase treatment
retention and success. In addition, this group of women is a very specific population with
specific needs. Most of them, when identified as pregnant and opiate addicted, are
referred for short term hospitalization for opiate detoxification or treated with methadone
or suboxone as a safer substitute (Veilleux, Colvin, Anderson, York, & Heinz, 2010). They
often have difficulties withdrawing from opiates whether they are placed on
detoxification or whether a drug replacement with methadone or suboxone is utilized
(Veilleux et al., 2010). This study was designed to uncover which treatment modality is
utilized most often by the women in general and what, if any, differences are found in
need for adjunct medication for each treatment approach.
Research Questions
What is the preferred method of treatment for opiate addicted pregnant women
when they are initially hospitalized and how is frequency of prn usage during treatment
associated with their disposition at discharge?
Background and Significance
Illicit drugs were consumed by 5.1% of pregnant women in the United States in
the year 2009, compared to 9.3% of women in the general population (Young, 2009).
The prevalence rates of substance abuse during pregnancy ranged from 1.3 to 18% during
the 1990s, with the rates increasing over the past two decades (Bertsch, Mullins, &
Chaffin, 2006). It is important to note that the infants of women with opiate addiction
were born with NAS, which resulted in significant respiratory distress, low birth weight,
feeding difficulties and seizures. Also, the newborns with NAS were more likely to be
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covered by Medicaid. According to Patrick (2012), mean hospital charges for these
infants rose from $39,400 to $53,400 between 2000 and 2009, compared with a rise from
$6,600 to $9,500 for all other hospital births over the same period. Solutions to decrease
the number of opiate users and newborns exposed to opiates should be of utmost concern
and priority due to the risks it poses to the newborn child and the high healthcare costs
associated with treating the newborn with NAS.
Theoretical Framework
The study’s theoretical framework is the Disease Model of Addiction. The
Disease Model of Addiction proposes that addiction of any kind has biological,
neurological, genetic, and environmental sources of origin. The disease model involves
set factors that make a person susceptible to addiction be it either genetic predisposition
or psychological damage that occurred during childhood or both factors (Peele, 1988).
When this susceptible person is exposed to drugs and or environmental stress then drug
addiction is likely to result which then leads to a host of other problems. This model fits
when applied to the women in this study as the majority of the women reported a family
member with addiction issues and a large majority of the women also reported a history
of sexual abuse as a child or adolescent and current physical abuse in relationships.
Design and Methods
DESIGN:
The proposed study was based on a descriptive retrospective medical record
review of opiate addicted pregnant women hospitalized on a behavioral unit at a large
medical center in a southeastern state of the United States and that all study procedures
were approved by the medical review board of the sponsoring institution.
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SAMPLE:
The convenience sample consisted of all pregnant opiate addicted women
hospitalized at Samaritan Hospital Behavioral Health from January 1, 2012 to December
31, 2012.
MEASURES/INSTRUMENTS:
Demographic Variables: Demographic variables included years of age, ethnicity,
educational level, marital status, and presence of existing psychiatric disorder and type of
opiate used (heroin, oxycodone etc.), age of first use, years of use, number of previous
detoxification attempts, whether they are a tobacco smoker, gestational age of fetus and
how many living children they had currently not counting present pregnancy.
Outcome variables: The primary outcome variable was preferred method of treatment
(detoxification, methadone maintenance, subutex) as stated by the patient upon
admittance to the inpatient facility. The secondary outcome measure was amount of
PRNs used (in counts) from day 1 to day 5 of inpatient hospitalization. In addition, the
average prn usage (across the 5 days of admission) were determined. Finally, information
on discharge disposition [detoxification vs. methadone maintenance vs. suboxone
(buprenorphine) vs left Against Medical Advice (AMA)] was obtained from the charts.
PROCEDURE:
The sources of research material were obtained from the medical charts of
previously admitted patients on a behavioral health unit who had a diagnosis of opiate
addiction and pregnancy. Since this study involves a retrospective chart review of
existing data, no subjects were recruited. No identifiers were obtained from subject
charts and each chart reviewed was given a unique code. An official letter of support
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from the major medical center granting access to the charts for this research purpose was
granted, giving permission for this research record review. Medical record personnel
were utilized to obtain the charts once IRB permission was granted. The IRB approval
processes were followed and the procedure for a Medical Expedited Exempt IRB Review
was followed. Once the research study was approved, data was securely stored on
removable device kept with the researcher. The sample included medical records of all
pregnant women with opiate addiction hospitalized at Samaritan Behavioral Health
during a specific time period (Jan 2012 to Dec. 31, 2012).
DATA ANALYSIS:
The primary outcome measure was an analysis of the preferred method of
treatment as stated by the patient upon admittance to the inpatient facility. Differences in
treatment completion were calculated using chi-square analyses for categorical and
ordered categorical values (with Fisher’s exact test for cells with lower than expected cell
count), and using t-tests or Mann-Whitney U tests for continuous variables (which did not
meet the assumption of equality of variance based on Levine’s equality of variance test).
The secondary outcome measure was amount of PRNs used from day 1 to day 5
of inpatient hospitalization and how it related to disposition at discharge. Analysis of
Variance (ANOVA) tests were used to assess mean differences in total and average
(across the 5 days) prn usage by disposition at discharge (i.e., detox vs. methadone
maintenance vs. suboxone (buprenorphine) vs left AMA).
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Results
Sample Characteristics
The sample included 161 women. The sample was primarily white (96.3%), 26.4
years of age, high school or GED (65.8%). One-half of the sample were single and not in
a relationship and were an average at 19.7 weeks of gestation. The majority were
tobacco users (91.3%) and using opiates in general (42.2%) or a combination of opiates
and other illicit drugs (34.8%). On average women started using opiates at age 19.3 and
had been using for nearly 7 years. More than one-third of the women had a co-morbid
psychiatric illness. Of those attending the methadone inpatient program, 80.7%
completed (stayed 5 days). There were no significant differences in patient
characteristics between those who completed and did not complete the program (See
Table 1).
Preferred Method of Treatment During Hospitalization
When women were asked their preferred method of treatment, the majority
preferred detoxification (see figure 1). The preference for method of treatment did not
vary by demographic or other patient characteristics.
Association between PRN use and Discharge Disposition
There were significant differences in the frequency of PRN use by patients’
disposition at discharge. Patients who left before treatment was complete/AMA, had
significantly lower scores on total PRN use and average PRN use as compared to those
who preferred to be detoxed from opiates or who had plans to be maintained on subutex
or methadone upon discharge. Specifically, patients who left early/AMA or before the 5
days of treatment used less PRNs (Mean amount of total prn use = 5.6) whereas
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participants who stayed the entire 5 days of treatment and did not leave AMA used more
PRNs (Mean amount of total prn use = 13.2). Patients who left before treatment was
complete/AMA, had significantly lower scores on total PRN use and average PRN use as
compared to those who preferred to be detoxed from opiates or who had plans to be
maintained on suboxone, subutex or methadone upon discharge (see Table 3). As
indicated in Table 3, average PRN use among non-completers/AMA was lower compared
to completers or those who were detoxed from opiates or chose maintenance medications
Discussion
The standard of care for an opiate addicted pregnant woman would necessitate a
universal substance use screening during pregnancy and referral to treatment such as
maintenance therapy if warranted (Mattick et al., 2009). Evidence based practice and a
review of the literature suggests that when identified as pregnant and opiate addicted,
women are referred for short term hospitalization for opiate detoxification and then
treated with methadone or suboxone as a safer substitute on a maintenance basis (Martin
et al., 2014: Kahila et al., 2007). A comprehensive, standard of care program regimen
improves maternal and neonatal outcomes as well as reduces associated adverse health
consequences (Jones, O’Grady, Malfi & Tuten, 2008; Kaltenbach & Finnegan, 1998).
Methadone, Suboxone and Subutex treatments, also known as drug replacement therapy,
is the preferred alternative to detoxification according to most research, as research has
shown that it is safer and more effective for the addicted mother and fetus.
The treatment needs as expressed by the study sample did not match what the standard of
care suggests. Greater than 90% desire to detoxify from drugs completely as verbalized
by the patient (see Figure 1). No other study, known to this author, have asked patients

54

their preference for treatment. Addicted women who completely detox often relapse if
they do not go to extended treatment and receive drug replacement therapy (Kahila et al.,
2007). However treatment and drug replacement therapy is often difficult to obtain and
afford, which may have affected the participants’ stated choice of “detox.” In addition
they may have endorsed detox because participants felt that it was the “right” thing for
their unborn child. Nonetheless, this finding is consistent with the findings according to
Martin et al., (2014), who state that only about a third of the women hospitalized when
pregnant for opiate addiction are placed on medication assisted therapy despite the
standard of care for opioid abuse in pregnancy.
Alternatively, the poor endorsement of drug replacement therapy at discharge by
the study sample may reflect the lack of available and accessible treatment facilities to for
this population and the financial limitations that come with such treatment. This is
consistent in other studies that highlight the multiple barriers pregnant women with
addition problems face with a lack of suitable treatment options and challenges in finding
and accessing treatment (Stone, 2015). These potential barriers necessitate the further
expansion of treatment programs and social services to meet the needs of substance-using
women (Stone, 2015). This need is highlighted by a qualitative study with 30 cocaine
using women that found that optimizing the benefit of comprehensive services for
addicted women requires their provision within a multilevel model of substance abuse
treatment, including long- and short-term residential and intensive outpatient settings
(Kaltenbach and Finnegan, 1998).
In addition, in the current study, PRN use was significantly associated with
discharge disposition. The more the study sample received PRNs, the more likely they
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were to stay the entire detoxification period and not leave against medical advice. Those
who left against medical advice received the fewest PRNs; this finding was significant
when examining both total PRN usage and when examining PRN usage based on the total
stay. This could suggest that comfort level of the patient may be a factor in the patient
completing treatment. Those who ask for and receive PRNs may be trying to decrease
their discomfort while those who are not may have lower tolerance for withdrawal or be
less motivated to engage in treatment. Often those patients who left AMA were patients
who returned again once or twice for detox during the same pregnancy. This is consistent
with other studies which reported that few opioid addicted women can handle abstinence
from opioids (Unger et al., 2010; Martin et al., 2009).
Limitations
The limitations in this study include the small sample size (161) and the fact that
it encompasses a geographic region that may not capture true demographics typical of the
population at large. In this study, for example, 96.3% of the participants were White,
which may lead a researcher to believe it is not a problem for other ethnicities.
An additional limitation is that since this study is a retrospective analysis of existing data,
there could have been different study variables which could have affected the outcomes
of the study that were unavailable. For example, the data on participants’ withdrawal
scores were unreliable because there were too many missing records from the charts. In
other words, often times opiate withdrawal checks were not done the requisite or ordered
times that they were supposed to be done. In addition, participant’s motivation for detox
was not measured. As a result, it is not possible to tell if those who left AMA were less
motivated to complete treatment as compared to those who completed treatment. Future
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studies may assess patient motivation as a possible predictor of discharge disposition and
treatment completion.
A strength of this study is that it is the first of its kind. Opiate addiction among
pregnant women is a subject which has been reviewed extensively for neonatal
abstinence effects and the effects of drug replacement therapies but it has not been
reviewed in terms of the patient experience, preference for treatment and success of
treatment long term for the woman and her children.
Implications for Practice
This study can be used as a beginning blueprint for investigating what pregnant
women with opiate addiction need for treatment from an inpatient perspective. It can
begin the discussion on what retains a woman in treatment, what is important to do for
the woman while she is in treatment, and what could be her treatment needs long term in
order for her to remain drug free and improve her quality of life? It can help healthcare
workers examine the stigma they place on the opiate pregnant addicted woman and shape
attitudes and practice.
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Table 1. Sample characteristics by program completion
Total
(N =161)

Completed
(n = 130)

Not Completed
(n = 31)

N

%

n

%

n

%

155
4
1
1

96.3
2.5
0.6
0.6

124
4
1
1

95.4
3.1
0.8
0.8

31
0
0
0

100.0
0.0
0.0
0.0

51
94
4

34.2
63.1
2.7

44
79
3

34.9
62.7
2.4

7
15
1

30.4
65.2
4.3

82
18
37
19
2
3

50.9
11.2
23.0
11.8
1.2
1.9

73
14
25
13
2
3

56.2
10.8
19.2
10.0
1.5
2.3

9
4
12
6
0
0

29.0
12.9
38.7
19.4
0.0
0.0

Heroin
Opiates in General
Oxycodone/OxyContin
Suboxone
Methadone
Combination of Many

10
68
23
2
2
56

6.2
42.2
14.3
1.2
1.2
34.8

7
55
18
0
2
48

5.4
42.3
13.8
0.0
1.5
36.9

3
13
5
2
0
8

9.7
41.9
16.1
6.5
0.0
25.8

Yes
No

147
14

91.3
8.7

118
12

90.8
9.2

29
2

93.5
6.5

Co-Morbid Psychiatric Illness
Yes
No

60
101

37.3
62.7

52
78

40.0
60.0

8
23

25.8
74.2

Number of Detox Attempts
None
1 to 3
Greater than 3

70
69
22

43.5
42.9
13.7

54
57
19

41.5
43.8
14.6

16
12
3

51.6
38.7
9.7

Ethnicity
White
African American
Hispanic
Other
Education Level (missing=12)
Less than High School
High School/GED or greater
College Graduate
Marital Status
Single, not in relationship
Divorced/Separated
Non-Married, Living with Partner
Married
Non-Married, estranged from Partner
In relationship, not living with Partner
Type of Illicit Drug Use

Tobacco Use
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Table 2
Mean

SD

Mean

SD

Mean

SD

Age (years)

26.4

4.4

26.3

4.5

27.0

3.7

Gestational Age of Fetus (Weeks)

19.7

8.0

20.1

7.9

17.9

8.4

How Many Living Children

1.5

1.9

1.5

1.9

1.5

1.8

Age of First Use of Opiates in Years(missing = 4)

19.3

4.4

19.2

4.3

19.9

5.0

Duration of Use in Years (missing = 4)

6.9

4.9

6.8

4.8

7.3

5.6

*** Differences are calculated using chi-square analyses for categorical and ordered categorical values (with Fisher’s exact test for
cells with lower than expected cell count), and using t-tests or Mann-Whitney U tests for continuous variables (which did not meet the
assumption of equality of variance based on Levine’s equality of variance test).
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What is your preferred method of
treatment?
8.7%

Detox
Methadone Maintenance
91.3%

Figure 2 Preferred Method of Treatment
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Table 3. Differences in Frequency of PRN use by Disposition at Discharge and
Completion of Treatment
Disposition at Discharge
Methadone Maintenance (n=20)
Detox from Opiates (n=101)
Maintenance on Subutex (n=15)
Left on no RX/AMA (n=25)

Mean

SD

12.3
14.2
13.2
5.6

7.9
8.5
10.5
6.5

Mean

SD

Total PRN
F Statistic (DF)
7.0

P-Value
<.0001

Average PRN*
F Statistic (DF)
3.7

P-Value
.013

Disposition at Discharge
Methadone Maintenance (n=20)
2.5
1.6
Detox from Opiates (n=101)
2.9
1.7
Maintenance on Subutex (n=15)
2.8
2.2
Left on no RX/AMA (n=25)
1.7
1.4
Average PRN use is defined by the total PRN use/length of stay
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Practice Inquiry Project Conclusions

Opiate addiction is a complex multidimensional disease that affects every aspect
of the afflicted person’s life. This problem becomes more urgent during pregnancy,
because another life is involved. The evidence based literature has demonstrated the
degree to which opiate addiction and pregnancy has escalated in scope in this country.
The literature has also described the attempts at treatments for women who are pregnant
and opiate addicted with an emphasis on the utilization of drug replacement therapy as
the safest alternative for the woman and the child. However, the problems that opiate
addictions encompass go beyond the pregnancy and expand into psychosocial,
physiological, psychological, financial, legal and ethical realms. Thus this problem needs
the focus of an APN to tackle some of its issues from the policy arena in order to create
long term lasting effects for the health of this vulnerable population. The access to
treatment is limited, and funding for standard drug replacement therapies is lacking. The
women then attempt to detox off of all drugs and more often than not fail in that attempt.
The result even with a woman who receives adequate drug replacement therapy is an
infant born with neonatal abstinence syndrome, a costly expense to the system. Women
who do seek treatment are often stigmatized by society and even by the healthcare
workers they seek treatment from. In addition, they often face legal consequences of
their drug use which could include losing custody of their children when they admit to
needing help with their drug addiction.
Why are so many young women abusing drugs? What are their stressors in life?
Why do they use drugs when others don’t? Is prevention a possibility here? In the
meantime how do we effectively treat these women in a manner that is consistent with
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what they want and need? This research has basically raised several more important
questions, and this researcher would like to go to the source for the answer, the women
themselves.
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